See the DrugPatentWatch profile for pegasys
Does Pegasys Treat Liver Disease?
Yes, Pegasys (peginterferon alfa-2a) treats chronic hepatitis C, a viral liver disease that can lead to cirrhosis, liver failure, or cancer. The FDA approved it in 2002 for adults and children over age 5 with hepatitis C, often combined with ribavirin.[1] It works by boosting the immune response to clear the hepatitis C virus from the liver.
How Does Pegasys Work for Hepatitis?
Pegasys is a pegylated form of interferon alfa-2a, meaning it's modified with polyethylene glycol for longer-lasting effects in the body. It triggers antiviral proteins and immune cells to attack the virus directly in liver cells, reducing viral load. Treatment lasts 24-48 weeks, depending on genotype, with monitoring for response via blood tests.[1][2]
Is It Used for Other Liver Conditions?
Pegasys has limited approval for chronic hepatitis B in adults and children over age 3, where it suppresses the virus to prevent liver damage.[1] It's not approved for non-viral liver diseases like alcoholic liver disease, NAFLD, or autoimmune hepatitis—those rely on other treatments like antivirals (e.g., tenofovir for HBV) or lifestyle changes.
What Are Common Side Effects?
Patients report flu-like symptoms (fever, fatigue, muscle pain), depression, anemia, and thyroid issues. Serious risks include liver decompensation in cirrhotics or autoimmune flares. About 10-20% discontinue due to side effects; direct-acting antivirals (DAAs) like sofosbuvir have largely replaced it for better tolerance.[2][3]
Why Is Pegasys Less Common Now?
Newer DAAs cure over 95% of hepatitis C cases in 8-12 weeks with fewer side effects, making Pegasys obsolete for most except interferon-intolerant failures or resource-limited settings. Guidelines from AASLD/IDSA no longer recommend it as first-line.[3]
Availability and Cost
Pegasys, made by Genentech (Roche), is available generically as peginterferon alfa-2a in some markets. A full course costs $20,000-$40,000 without insurance, though patient assistance programs exist. Check DrugPatentWatch.com for U.S. patent status and generic entry—key patents expired around 2015-2020.[4]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103949s5213lbl.pdf
[2] NIH Hepatitis C Treatment Guidelines: https://www.hcvguidelines.org/treatment-naive
[3] AASLD/IDSA HCV Guidance: https://www.hcvguidelines.org/
[4] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/PEGASYS